Heart cells are growing from the inside out
Deep within the architecture of the human heart, researchers at the University of Pennsylvania have discovered the molecular logic governing how heart cells choose to grow — a question that has shadowed cardiology for decades. By mapping the roles of microtubule stability and the ERK signaling pathway, the team has illuminated why some stressed hearts stretch thin while others grow dangerously thick, tracing two distinct remodeling fates back to identifiable cellular switches. This knowledge does not yet cure cardiomyopathy, but it reframes the disease: not as an inevitable consequence of stress, but as a misdirection of growth that science may one day correct.
- Two of the most common heart muscle diseases — one that stretches the heart dangerously thin, another that thickens it into stiffness — have long resisted explanation at the cellular level, leaving millions of patients with few options beyond managing symptoms.
- Researchers found that a single variable — whether the heart cell's internal protein scaffolding is stable or unstable — determines whether the cell expands sideways or lengthens, a discovery that reframes cardiomyopathy as a problem of misdirected architecture.
- A second molecular system, the ERK signaling pathway, acts like a biased postal service inside the cell, routing building materials inward rather than outward under pathological stress — a pattern absent in healthy exercise-driven heart growth, suggesting it could be targeted without disrupting normal adaptation.
- FDA-approved drugs already exist that touch both microtubule stability and ERK signaling, but they act broadly across the body, meaning the immediate challenge is developing delivery mechanisms precise enough to reach heart muscle cells without systemic consequences.
- The research marks a conceptual turning point — from managing the downstream damage of heart failure toward intervening in the upstream cellular decisions that determine whether a stressed heart remodels harmfully in the first place.
Inside every heart cell is a microscopic skeleton built from protein filaments called microtubules. Researchers have long known this framework shifts under cardiac stress, but the governing logic remained elusive. Now, a team at the University of Pennsylvania's Perelman School of Medicine has identified the molecular switches that determine whether heart cells grow wider or longer — and why that distinction matters enormously for treating heart failure.
The key insight is elegant: microtubule stability acts as a directional signal for growth. Stabilized microtubules push cells to expand sideways; destabilized ones prompt lengthwise stretching. By manipulating this stability in mouse models and human heart tissue, professor Benjamin Prosser and his team demonstrated that cardiac remodeling under stress is not a single process but at least two distinct pathways — each corresponding to a different disease. Dilated cardiomyopathy, where the heart stretches thin and weak, follows one path. Hypertrophic cardiomyopathy, where the muscle thickens and stiffens, follows the other.
A companion study added a second layer of understanding. The ERK signaling pathway, the researchers found, functions like a biased internal delivery system — routing materials exported from the cell's nucleus preferentially to the cell's interior rather than its edges. This inside-out pattern of growth appears specifically under pathological stress, such as hypertension, and is notably absent during the beneficial adaptations that come with regular exercise. The implication is significant: ERK may be a switch that flips only when something has gone wrong, making it a potentially precise therapeutic target.
The researchers also found that microtubule stability influences how well heart cells adhere to one another at their junctions, adding another dimension to what controlling this system might achieve. Drugs that modulate both microtubules and ERK signaling already exist and carry FDA approval, but they were designed for other conditions and act throughout the body. The next challenge is precision — engineering ways to deliver these interventions specifically to heart muscle cells, turning a broad pharmaceutical toolkit into targeted cardiac medicine.
For those living with cardiomyopathy or at risk of heart failure, the research signals a shift in ambition: from managing the consequences of a remodeling heart to understanding — and eventually redirecting — the cellular decisions that set disease in motion.
Inside every heart cell lies a microscopic architecture—a skeleton made of protein filaments called microtubules that gives the cell its shape and structure. For years, researchers knew that this internal framework changed when the heart was under stress, but they didn't understand how or why. Now, a team at the University of Pennsylvania's Perelman School of Medicine has cracked open that mystery, revealing the molecular switches that determine whether heart cells grow wider or longer, and what that means for treating heart failure.
The discovery hinges on a simple but elegant principle: the stability of microtubules acts like a traffic director for cellular growth. When these filaments are stabilized, heart cells expand sideways, becoming wider. When they destabilize, cells stretch lengthwise instead. Benjamin Prosser, a professor of physiology who led the research, and his team demonstrated this by manipulating microtubule stability in both mouse models and human heart tissue samples. The findings, published in the journal Science, revealed something unexpected: there isn't one way for the heart to remodel under stress—there are at least two distinct pathways, each producing a different kind of growth.
This matters because two of the most common forms of cardiomyopathy—diseases that damage the heart muscle—follow these exact patterns. Dilated cardiomyopathy occurs when the heart stretches too much, becoming thin and weak. Hypertrophic cardiomyopathy happens when the heart muscle thickens excessively, stiffening the organ and making it harder to pump blood. If researchers could control which direction a stressed heart cell grows, they might be able to prevent these dangerous remodeling patterns before they develop into full-blown heart failure.
But microtubule stability is only part of the story. In a companion study published in Science Signaling, Prosser's team identified a second crucial player: the ERK signaling pathway. This molecular messenger acts like a postal service inside the cell, determining where resources exported from the nucleus—the cell's supply depot—actually get delivered. The researchers found that ERK preferentially sends these building materials to the interior of the cell rather than to its outer edges. This bias toward internal growth explains why certain conditions, particularly hypertension, cause the heart muscle to thicken. Keita Uchida, a research associate in the lab, noted that this pattern of growth from the inside out doesn't occur during healthy cardiac adaptation, such as the beneficial changes that happen with regular exercise.
The ERK pathway appears to be a switch that flips only under pathological stress, not during normal physiological demands. This distinction is crucial because it suggests that blocking or modulating ERK activity might prevent harmful remodeling without interfering with the heart's natural ability to strengthen itself through exercise. The researchers also discovered that stabilized microtubules strengthen the intercalated discs—the adhesive junctions where heart muscle cells connect to one another—while destabilized microtubules weaken these critical contact points. This dual effect means that controlling microtubule stability could influence not just how cells grow, but how well they stick together.
The pharmaceutical toolkit already exists. The FDA has approved several drugs that either adjust microtubule stability or modulate ERK signaling, but these medications were developed for other purposes and affect cells throughout the body. Prosser emphasized that any therapeutic approach based on these findings would need refinement to target heart muscle cells specifically, avoiding the collateral damage that broad-spectrum drugs can cause. The challenge now is precision: taking what researchers have learned about the molecular mechanics of heart cell growth and translating it into treatments that can reach the right cells at the right time without triggering unwanted effects elsewhere.
For patients living with cardiomyopathy or at risk of heart failure, this research represents a shift from treating symptoms to addressing the underlying cellular mechanics that drive disease. The mystery of how and why heart cells reshape under stress has been solved. What comes next is the harder work of turning that knowledge into medicine.
Citações Notáveis
Now that we know what is doing the work and what guides it, that opens the door to targeting these mechanisms and correcting abnormal growth.— Benjamin Prosser, senior author of the studies
We were not expecting to find two unique ways for the heart to grow thicker or thinner when we started this research.— Emily Scarborough, first author on the Science paper
A Conversa do Hearth Outra perspectiva sobre a história
Why does it matter whether a heart cell grows wider or longer? Aren't both kinds of growth bad when the heart is stressed?
Not exactly. The direction of growth determines the functional consequence. A heart that thickens—grows wider—becomes stiff and struggles to relax between beats. A heart that stretches—grows longer—becomes thin and weak, unable to pump with force. They're different diseases with different dangers. If you could steer growth in one direction or prevent it altogether, you'd have a tool against both.
So the microtubules are like a switch that controls which way the growth goes?
More like a dial. When they're stable, the cell grows sideways. When they're unstable, it grows lengthwise. The researchers could actually flip this dial in the lab. That's what made the finding so powerful—it's not just observation, it's control.
And the ERK pathway is something different entirely?
It's the delivery system. The nucleus packages up materials the cell needs to grow, and ERK decides where those packages go. In a healthy heart during exercise, ERK stays quiet. But under pathological stress—like chronic high blood pressure—ERK activates and routes everything inward, causing the muscle to thicken. It's like the cell is being told to build from the inside out.
Can you just block ERK and solve the problem?
That's the trap. ERK controls growth in cells all over your body. Block it everywhere and you create chaos. The real challenge is finding a way to silence it only in heart muscle cells, only when it's causing harm. That's why existing drugs won't work as-is—they're too blunt an instrument.
How close are we to an actual treatment?
The science is solid. The drugs exist. But there's still the engineering problem of delivery and specificity. That's not a small thing, but it's also not insurmountable. This research gives doctors a target they didn't have before.